Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.

Bartlett NL, Sehn LH, Assouline S, Giri P, Kuruvilla J, Schuster SJ, Yoon SS, Fay K, Hess G, Dreyling M, Gutierrez NC, Cybulski E, Sabalvaro F, Penuel E, Teodoro V, Tracy S, Kuruvilla D, Chen J, Wiebking V, Wei MC, Budde LE

Open source

DOI: 10.1002/ajh.70225
Published: 2026 May
Container: American journal of hematology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1002/ajh.70225,
  title = {Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.},
  author = {Bartlett NL and Sehn LH and Assouline S and Giri P and Kuruvilla J and Schuster SJ and Yoon SS and Fay K and Hess G and Dreyling M and Gutierrez NC and Cybulski E and Sabalvaro F and Penuel E and Teodoro V and Tracy S and Kuruvilla D and Chen J and Wiebking V and Wei MC and Budde LE},
  year = {2026},
  journal = {American journal of hematology},
  doi = {10.1002/ajh.70225},
  url = {https://doi.org/10.1002/ajh.70225}
}

RIS

TY  - JOUR
TI  - Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.
AU  - Bartlett NL
AU  - Sehn LH
AU  - Assouline S
AU  - Giri P
AU  - Kuruvilla J
AU  - Schuster SJ
AU  - Yoon SS
AU  - Fay K
AU  - Hess G
AU  - Dreyling M
AU  - Gutierrez NC
AU  - Cybulski E
AU  - Sabalvaro F
AU  - Penuel E
AU  - Teodoro V
AU  - Tracy S
AU  - Kuruvilla D
AU  - Chen J
AU  - Wiebking V
AU  - Wei MC
AU  - Budde LE
PY  - 2026
JO  - American journal of hematology
DO  - 10.1002/ajh.70225
UR  - https://doi.org/10.1002/ajh.70225
ER  -

APA

NL, B., LH, S., S, A., P, G., J, K., SJ, S., SS, Y., K, F., G, H., M, D., NC, G., E, C., F, S., E, P., V, T., S, T., D, K., J, C., V, W., MC, W., & LE, B. (2026). Fixed-Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis.. American journal of hematology. https://doi.org/10.1002/ajh.70225

Source records

pubmed · retrieved 2026-09-26T05:56:53.362Z